VAN HOUTE HANS (Chief Financial Officer) sold 10.6% of their position (4.76K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $116.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 8/5/2026ACC: 0001817217-26-000012
Officer· Chief Financial Officer
Since Jul 2020
-4.76K
Net shares
Net seller
$116.0K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.76K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−1.79K
Price / share
$23.89
Trade value
$42.86K
% of position
4.0%
8/4/2026
44.93K→43.13K
Common Stock
Direct
Shares
−2.97K
Price / share
$24.65
Trade value
$73.13K
% of position
6.9%
8/4/2026
43.13K→40.17K
Total
Net shares
−4.76K
Net value
-$115.99K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/4/2026 | S · Sale | −1.79K | $23.89 | $42.86K | 4.0% | 44.93K | 43.13K |
| Common Stock Direct | 8/4/2026 | S · Sale | −2.97K | $24.65 | $73.13K | 6.9% | 43.13K | 40.17K |
| Total | −4.76K | -$115.99K | ||||||
Derivative Transactions0
No derivative transactions reported